HIGHLIGHTS
SUMMARY
Significant improvements are continuously made in the treatment of ovarian carcinoma, but this disease continues to place a tremendous burden on healthcare systems, especially in countries with a low index of human development. The scope of the study is to provide an extensive review of the efficacy-safety ratio of angiogenesis-inhibitors-based therapies in ovarian cancer, thus providing a better evaluation and selection tool for clinicians. The second criterion used was that the publications contained a reference to angiogenesis or antiangiogenetic therapy-(vascular endothelial growth factor OR angiogenesis inhibitor OR VEGF OR VEGFR . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.